DNA Vaccines: Technologies and Global Markets

Table of Contents

DNA Vaccines: Technologies and Global Markets

Chapter- 1: INTRODUCTION -- Complimentary

• STUDY GOALS AND OBJECTIVES
• REASONS FOR DOING THE STUDY
• INTENDED AUDIENCE
• SCOPE OF REPORT
• METHODOLOGY
• INFORMATION SOURCES
• RELATED BCC REPORTS
• ANALYST CREDENTIALS
• BCC ONLINE SERVICES
• DISCLAIMER

Chapter-2: SUMMARY

• SUMMARY
• SUMMARY TABLE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
• SUMMARY FIGURE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
• SUMMARY (CONTINUED)

Chapter-3: OVERVIEW

• INTRODUCTION
  • TABLE 1 CLINICAL STATUS OF DNA VACCINES, AS OF JULY 2009 (NUMBER)
• DNA VACCINE TECHNOLOGIES COVERED IN THIS REPORT
  • TABLE 2 SCOPE OF THIS REPORT
• GLOBAL MARKET FOR DNA VACCINES
  • TABLE 3 GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
  • TABLE 4 GLOBAL VALUE OF HUMAN DNA VACCINE MARKET BY INDICATION, THROUGH 2014 ($ MILLIONS)
• FORCES DRIVING DNA VACCINE MARKET GROWTH
  • TABLE 5 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
• LIFE CYCLE STATUS OF DNA VACCINE TECHNOLOGIES
  • TABLE 6 LIFE CYCLE STAGE OF VACCINE TYPES
• COMMERCIAL STATUS OF DNA VACCINE TECHNOLOGIES
  • TABLE 7 COMMERCIAL STATUS OF DNA VACCINES
• DNA VACCINE INDUSTRY
  • TABLE 8 DNA VACCINE INDUSTRY STRUCTURE

Chapter-4: DNA VACCINE TECHNOLOGIES

• HISTORY
  • TABLE 9 DNA VACCINE HISTORY
• THE HUMAN IMMUNE SYSTEM
  • TABLE 10 COMPONENTS OF THE IMMUNE SYSTEM
• THE HUMAN IMMUNE SYSTEM (CONTINUED)
• VACCINES
• VACCINE EVOLUTION
  • FIGURE 1 EVOLUTION OF VACCINE TECHNOLOGIES
• VACCINE TYPES
  • TABLE 11 VACCINE TYPES
• Technology Life-Cycle Stage of Vaccine Types
  • TABLE 12 TECHNOLOGY LIFE-CYCLE STAGE OF VACCINE TYPES
• DNA VACCINES
• INTRODUCTION
  • FIGURE 2 MECHANISM OF ACTION OF A DNA VACCINE
• CHANGING VACCINE PARADIGM
  • TABLE 13 CHANGING VACCINE PARADIGM
  • TABLE 14 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES
• Changing Vaccine Paradigm (Continued)
  • FIGURE 3 SAFETY AND EFFICACY PROFILE OF DNA VERSUS VIRAL-VECTOR VACCINES
• FUNCTION AND SCOPE OF DNA VACCINES
  • FIGURE 4 DNA VACCINE FUNCTION AND MARKET SCOPE
  • TABLE 15 EMERGING COMPETITIVE LANDSCAPE FOR DNA VACCINES
• CANCER DNA VACCINES
  • TABLE 16 CANCER VACCINE TYPES
• DNA VACCINE TECHNOLOGY VALUE CHAIN
  • FIGURE 5 DNA VACCINE TECHNOLOGY VALUE CHAIN
  • TABLE 17 TECHNOLOGY DRIVERS FOR DNA VACCINE VALUE CHAIN
• ANTIGEN DISCOVERY
• PLASMID DESIGN
  • TABLE 18 PLASMID DESIGN OBJECTIVES
  • TABLE 19 WAYS TO OPTIMIZE MAMMALIAN GENE EXPRESSION IN PLASMID DNA
• Plasmid Design (Continued)
• PLASMID MANUFACTURE
  • FIGURE 6 CONVENTIONAL AND PLASMID DNA VACCINE PRODUCTION PROCESS
  • TABLE 20 DNA PLASMID QUALITY COMPARSION
• DELIVERY TECHNOLOGIES
  • TABLE 21 COMPARISON OF DNA DELIVERY TECHNOLOGIES
• Uncomplexed pDNA
• Electroporation
  • FIGURE 7 EP PROCESS SCHEMATIC
• Liposomes
• Gold Particles
• Nanoparticles
• Bacterial Ghosts
• Bacteriophages
• Viruses
  • TABLE 22 IN VIVO VIRAL VECTOR TECHNOLOGIES COMPARED
• Viruses (Continued)
• TARGETING TECHNOLOGIES
  • FIGURE 8 STRATEGIES FOR TARGETING DENDRITIC CELLS
• ADJUVANT TECHNOLOGIES
  • TABLE 23 DNA VACCINE ADJUVANT TECHNOLOGIES
• DNA VACCINE TECHNOLOGY NEEDS
  • TABLE 24 TECHNOLOGY NEEDS FOR DNA VACCINES
• DNA Vaccine Technology ...... (Continued)

Chapter-5: DNA VACCINE APPLICATIONS

• RESEARCH TOOLS APPLICATIONS
• CLINICAL APPLICATIONS
• OVERVIEW TO DNA VACCINE CLINICAL TRIALS PROCESS
  • TABLE 25 DNA VACCINE DEVELOPMENT FLOWSHEET
  • TABLE 26 DNA VACCINE PRECLINICAL DEVELOPMENT STEPS
  • FIGURE 9 FUTURE VACCINE CLINICAL TRIALS OVERVIEW
• Overview to DNA ...... (Continued)
• DNA VACCINE CLINICAL TRIALS SUMMARY
  • TABLE 27 DNA VACCINES CLINICAL TRIALS SUMMARY BY DISEASE TYPE, AS OF JULY 2009
  • TABLE 28 DNA VACCINES CLINICAL TRIALS SUMMARY BY DELIVERY TECHNOLOGY, AS OF JULY 2009
  • TABLE 29 DNA VACCINES CLINICAL TRIALS SUMMARY BY VACCINE TYPE, AS OF JULY 2009
  • TABLE 30 DNA VACCINES CLINICAL TRIALS SUMMARY BY VACCINE TYPE AND INDICATION, AS OF JULY 2009
• CANCER DNA VACCINE CLINICAL TRIALS
  • TABLE 31 CANCER DNA VACCINES CLINICAL TRIALS, AS OF 2009
  • TABLE 31 (CONTINUED)
  • TABLE 31 (CONTINUED)
• Melanoma
• Melanoma (Continued)
• Prostate Cancer
• Breast Cancer
• Multiple Cancers
• INFECTIOUS DISEASE DNA VACCINES
  • TABLE 32 INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF JULY 2009
  • TABLE 32 (CONTINUED)
• HSV
• HPV
• Influenza
• Influenza (Continued)
• Influenza (Continued)
• SARS
• Dengue
  • TABLE 33 DENGUE VACCINE LANDSCAPE, AS OF JULY 2009
• HBV
  • TABLE 34 HBV THERAPEUTIC LANDSCAPE, AS OF JULY 2009
• HBV (Continued)
• HCV
• Japanese Encephalitis
  • TABLE 35 JAPANESE ENCEPHALITIS VACCINE LANDSCAPE, AS OF JULY 2009
• CMV
  • TABLE 36 CMV VACCINE LANDSCAPE, AS OF JULY 2009
• HIV
  • TABLE 37 HIV DNA VACCINES CLINICAL TRIALS, AS OF JULY 2009
  • TABLE 37 (CONTINUED)
  • TABLE 37 (CONTINUED)
  • TABLE 37 (CONTINUED)
• HIV (Continued)
• BIODEFENSE DNA VACCINES
  • TABLE 38 BIODEFENSE DNA VACCINES CLINICAL TRIALS, AS OF JULY 2009
• ANIMAL HEALTH DNA VACCINES
  • TABLE 39 ANIMAL HEALTH DNA VACCINES CLINCAL PIPELINE, AS OF JULY 2009
  • TABLE 40 WEST NILE VIRUS HUMAN VACCINES LANDSCAPE, AS OF JULY 2009

Chapter-6: DNA VACCINE INDUSTRY

• VACCINE INDUSTRY STRUCTURAL SHIFTS
  • TABLE 41 VACCINE INDUSTRY STRUCTURAL SHIFTS
• INDUSTRY STRUCTURE
  • TABLE 42 VACCINE INDUSTRY STRUCTURE: TRADITIONAL VERSUS EMERGING
  • FIGURE 10 MARKETING OF APPROVED VACCINES IN THE UNITED STATES, 2009 (%)
  • TABLE 43 COMPARISON OF VACCINES AND PHARMACEUTICALS BUSINESSES
• INDUSTRY STRUCTURE (CONTINUED)
• DNA VACCINE INDUSTRY COMPETITORS
  • TABLE 44 DNA VACCINE INDUSTRY COMPETITOR POSITION
• DNA VACCINE COMMERCIAL VALUE CHAIN
  • FIGURE 11 DNA VACCINE COMMERCIAL VALUE CHAIN
• DNA VACCINE COMPETITOR STRATEGIC POSITIONING
  • TABLE 45 LARGE PHARMA VACCINE COMPANY STRATEGIC FOCUS
  • TABLE 46 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
  • TABLE 47 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC MARKET FOCUS
  • TABLE 47 (CONTINUED)
  • TABLE 48 SPECIALIZED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
• INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES
  • TABLE 49 INDUSTRY ACQUISITIONS AND MERGERS, 2006 - 2009
• INDUSTRY ACQUISITIONS AND ...... (CONTINUED)
  • TABLE 50 DNA VACCINE STRATEGIC ALLIANCES
• INDUSTRY ACQUISITIONS AND ...... (CONTINUED)

Chapter-7: DNA VACCINE MARKETS

• GROWTH DRIVING FORCES
  • TABLE 51 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
• MARKET FORECASTS
• OVERVIEW
  • TABLE 52 GLOBAL VALUE OF PHARMACEUTICAL MARKET BY TYPE, THROUGH 2014 ($ MILLIONS)
• Overview (Continued)
• DNA VACCINE MARKETS BY END USE
  • TABLE 53 GLOBAL VALUE OF DNA VACCINES BY END USE, THROUGH 2014 ($ MILLIONS)
• DNA VACCINE RESEARCH TOOLS MARKETS
  • TABLE 54 GLOBAL VALUE OF DNA VACCINES RESEARCH TOOLS MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
• DNA VACCINE CLINICAL MARKETS
  • TABLE 55 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
• Strategic Positioning
  • FIGURE 12 DNA VACCINE STRATEGIC MARKET GRID
• Allergies
  • TABLE 56 DNA VACCINE ALLERGY MARKET OPPORTUNITIES
• Cancer Therapeutics
  • TABLE 57 CAUSE OF DEATH, WORLDWIDE, 2004 AND 2030 (% OF ALL DEATHS)
• Infectious Diseases
• DNA CANCER VACCINES MARKET
  • TABLE 58 GLOBAL VALUE OF CANCER CLINICAL DNA VACCINES BY INDICATION, THROUGH 2014 ($ MILLIONS)
  • TABLE 59 DNA VACCINE CANCER MARKET OPPORTUNITIES
• DNA Cancer Vaccines Market (Continued)
• Melanoma
• Solid Tumors (Including Ovarian, Breast and Small-Cell Lung Cancer)
• Pancreatic Cancer
• INFECTIOUS DISEASE DNA VACCINE MARKETS
  • TABLE 60 GLOBAL VALUE OF INFECTIOUS DISEASE CLINICAL DNA VACCINES MARKET BY INDICATION, THROUGH 2014 ($ MILLIONS)
• CMV
• HBV
• HPV
• HCV
• HIV
• ANIMAL HEALTH DNA VACCINE MARKETS
  • TABLE 61 GLOBAL VALUE OF ANIMAL HEALTH CLINICAL DNA VACCINES MARKET, BY INDICATION, THROUGH 2014 ($ MILLIONS)
• Canine Melanoma
• Equine West Nile Virus
• Leishmaniasis
• Feline Leukemia Virus
• Fish Vaccine Adjuvants
• BIODEFENSE DNA VACCINE MARKETS
  • TABLE 62 GLOBAL VALUE OF BIODEFENSE CLINICAL DNA VACCINES MARKET, BY END USE, THROUGH 2014 ($ MILLIONS)
• Biodefense DNA Vaccine Markets (Continued)
• Biodefense DNA Vaccine Markets (Continued)
• DNA VACCINE MARKETS BY DELIVERY TECHNOLOGY
  • TABLE 63 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY DELIVERY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
• DNA VACCINE MARKET BY FORMAT AND FUNCTION
  • TABLE 64 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY VACCINE FORMAT, THROUGH 2014 ($ MILLIONS)
  • TABLE 65 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY FUNCTION, THROUGH 2014 ($ MILLIONS)
• DNA VACCINES MARKET BY GEOGRAPHY
  • TABLE 66 GLOBAL VALUE OF DNA VACCINES MARKET, BY GEOGRAPHICAL REGION, THROUGH 2014 ($ MILLIONS)

Chapter-8: PATENT STATUS

• INTRODUCTION
  • FIGURE 13 PATENT SCOPE FOR DNA VACCINES
• DNA VACCINE PATENTS BY COMPANY AND TECHNOLOGY SUBCLASS
  • FIGURE 14 U.S., EP, AND WO INTEGRATED BIOTECHNOLOGY COMPANY DNA VACCINE-RELATED PATENTS AND PATENT APPLICATIONS, AS OF JULY 2009
  • FIGURE 15 U.S., EP, AND WO INTEGRATED BIOTECHNOLOGY COMPANY DNA VACCINE-RELATED PATENTS BY TECHNOLOGY SUBCLASS AND PATENT APPLICATIONS, AS OF JULY 2009
• DNA VACCINE PATENTS BY COMPANY ...... (CONTINUED)
  • FIGURE 16 U.S., EP, AND WO INTEGRATED BIOTECHNOLOGY COMPANY DNA VACCINE-RELATED PATENTS BY TECHNOLOGY SUBCLASS, AS OF JULY 2009
• ANTIGENS AND ASSOCIATED PDNA
• ANTIGENS AND ASSOCIATED PDNA (CONTINUED)
  • TABLE 67 FUNDAMENTAL DNA INFLUENZA VACCINE PATENTS
• DNA VACCINE PATENTS BY GEOGRAPHY
  • FIGURE 17 GEOGRAPHICAL REGIONS IN WHICH PATENTS HAVE BEEN GRANTED AND PATENT APPLICATIONS FILEDFOR INTEGRATED BIOTECHNOLOGY COMPANIES, AS OF JULY 2009 (%)
• KEY INDUSTRY PATENTS ON OTHER PARTS OF THE VALUE CHAIN
  • TABLE 68 FUNDAMENTAL PATENTS ON DNA VACCINE DELIVERY, TARGETING, AND ADJUVANTS
• LITIGATION STATUS
  • TABLE 69 IP LITIGATION STATUS
• IP POSITION OF SELECTED DNA VACCINE COMPANIES
• GENEART
• GENEXINE
  • TABLE 70 GENEXINE PATENT FAMILIES
• IMMUNOMIC THERAPEUTICS, INC. (ITI)
• VICAL

Chapter-9: COMPANY PROFILES

• ADIMMUNE
• ALDEVRON, LLC
• ALTEA THERAPEUTICS
• ALTHEA TECHNOLOGIES, INC.
• ANGES MG, INC.
• AVAX TECHNOLOGIES
• BACILLIGEN, INC.
• BAVARIAN NORDIC A/S
• BAYHILL THERAPEUTICS
  • TABLE 71 BAYHILL DNA VACCINE PIPELINE
• BIGDNA, LTD.
• BIOJECT MEDICAL TECHNOLOGIES, INC.
• CHANGCHUN BAIKE PHARMACEUTICAL CO., LTD.
• COBRA BIOMANUFACTURING, PLC
• CRUCELL
• CYTOGENIX, INC.
  • TABLE 72 CYTOGENIX DNA VACCINE PRECLINICAL PIPELINE
• CYTO PULSE SCIENCES, INC.
  • TABLE 73 CYTO PULSE PIPELINE
• PROSTATE CANCER STUDY
• COLORECTAL CANCER STUDY
• TOLERANCE STUDIES
• HIV STUDY
• CYTRX CORP.
• DENDREON CORP.
• DYNAVAX TECHNOLOGIES
• THE EUROVACC FOUNDATION
• FIT BIOTECH OYJ, PLC
• GENEART AG
  • TABLE 74 GENEART STRATEGIC ALLIANCES
• GENEART AG (CONTINUED)
• GENETIC IMMUNITY
  • TABLE 75 GENETIC IMMUNITY DNA VACCINE PIPELINE
• GENEXINE
  • TABLE 76 GENEXINE DNA VACCINE PIPELINE
  • TABLE 77 GENEXINE PATENT FAMILIES
  • TABLE 77 (CONTINUED)
• IL-12 MUTANT
• EFFICIENT DNA AND RAD VECTORS
• SAFE ADENOVIRAL VECTOR
• GENOMIDEA, INC.
• GENOVAC GMBH
• GENOVAC GMBH (CONTINUED)
• GENVEC, INC.
• GEOVAX LABS
• GLAXOSMITHKLINE
• GLAXOSMITHKLINE (CONTINUED)
• GREENPAK BIOTECH, LTD.
• HENDERSON MORLEY, PLC
• ICHOR MEDICAL SYSTEMS, INC.
  • TABLE 78 ICHOR DNA VACCINE PIPELINE
• IMMUNOGENETIX THERAPEUTICS, INC.
• IMMUNOMIC THERAPEUTICS, INC.
  • TABLE 79 IMMUNOMIC DNA VACCINE PIPELINE
• JRC-LAMP-VAX
• SRW-LAMP-VAX
  • TABLE 80 ITI STRATEGIC ALLIANCES
• IMMUNOVACCINE TECHNOLOGIES, INC.
• IN CELL ART
• INDIAN IMMUNOLOGICALS
• INTERCELL AG
• INVIVOGEN
• JUVARIS BIOTHERAPEUTICS, INC.
  • TABLE 81 JUVARIS DNA VACCINE PIPELINE
• LENTIGEN CORP.
• LIPOXEN, PLC
• MANNKIND CORP.
• MANNKIND CORP. (CONTINUED)
• MEDICAL MARKETING INTERNATIONAL GROUP, PLC
  • TABLE 82 GENVAX PIPELINE
• MERCK
  • TABLE 83 MERCK DNA VACCINE PIPELINE
• MERIAL
• MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
• MOLOGEN AG
• MULTIMERIC BIOTHERAPEUTICS, INC.
• NATURE TECHNOLOGY CORP.
• NIH VACCINE RESEARCH CENTER
• NOVARTIS
• OXFORD BIOMEDICA, PLC
• PFIZER
• PHYTOVATION BV
• PLASMIDFACTORY GMBH & CO.
• PROFECTUS BIOSCIENCES, INC.
• QED BIOSCIENCE, INC.
• SANOFI-AVENTIS
• STATENS SERUM INSTITUT
• SUPRATEK PHARMA
• TRIPEP
  • TABLE 84 TRIPEP THERAPEUTIC DNA VACCINE PIPELINE
• VAXGEN, INC.
• VAXXION THERAPEUTICS, INC.
• VAXONCO, INC.
• VECTURA GROUP, PLC
• VGX PHARMACEUTICALS, INC.
• VGX PHARMACEUTICALS, INC. (CONTINUED)
  • TABLE 85 INOVIO AND VGX DNA VACCINE CLINICAL TRIALS, AS OF JULY 2009
• VGX PHARMACEUTICALS, INC. (CONTINUED)
• VGXI, INC.
• VICAL, INC.
  • TABLE 86 VICAL STRATEGIC ALLIANCES
  • TABLE 87 VICAL DNA VACCINE PIPELINE
  • TABLE 87 (CONTINUED)
  • FIGURE 18 VICAL LINEAR DNA VACCINE STRATEGIC POSITIONING
• VIROMED CO., LTD.
• VIROMED CO., LTD. (CONTINUED)